文献速递运动医学关节外科

塞来昔布超越抗炎作用:在退行性肩袖肌腱病中缓解肌腱来源干细胞的衰老

Celecoxib, Beyond Anti-inflammation, Alleviates Tendon-Derived Stem Cell Senescence in Degenerative Rotator Cuff Tendinopathy.
PubMed 文献 · Am J Sports Med · 2022-06-06

该研究为受控实验室研究,从退行性肩袖肌腱病肌腱和健康腘绳肌腱分离肌腱来源干细胞(TDSC)。衰老TDSC条件培养基加速年轻TDSC衰老,塞来昔布可在一定程度上预防炎症衰老对年轻TDSC的不良影响并降低NF-κB通路水平。作者结论认为塞来昔布可预防炎症衰老诱导的TDSC衰老,可能延缓退行性肩袖肌腱病进展。

要点

  • 退行性肩袖肌腱病来源TDSC衰老标志物表达增加。
  • 衰老TDSC条件培养基加速年轻TDSC衰老,塞来昔布可部分预防此效应。
  • 塞来昔布降低衰老TDSC中升高的NF-κB通路水平并保留肌腱分化潜能。

核心结论

  • 塞来昔布治疗可预防炎症衰老诱导的TDSC衰老,可能有助于缓解退行性肩袖肌腱病的发展。

研究设计与样本

  • 受控实验室研究,从退行性肩袖肌腱病肌腱分离TDSC(S-TDSC)并与健康腘绳肌腱来源TDSC(Y-TDSC)比较。
  • 收集衰老TDSC条件培养基(SEN-CM)用于培养Y-TDSC,并分别在有或无塞来昔布条件下处理。

主要发现

  • S-TDSC显示衰老相关β-半乳糖苷酶活性增加,γ-H2AX、p21CIP1A、p16INK4A及衰老相关分泌表型因子表达增强。
  • SEN-CM加速Y-TDSC衰老进程,导致衰老标志物增加;塞来昔布处理可在一定程度上预防炎症衰老对Y-TDSC的不良影响。
  • NF-κB通路水平在SEN-CM组升高,使用塞来昔布后降低。
  • TDSC衰老减轻伴随肌腱分化潜能得以保留。

临床怎么用

  • 作者指出,塞来昔布作为一种常用非甾体抗炎药,除缓解肩袖肌腱病患者症状外,可能通过延缓TDSC衰老来推迟肩袖肌腱病发展和预防肩袖撕裂(原文为may defer、may prevent)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Degenerative rotator cuff tendinopathy (RCT) is associated with the senescence of tendon-derived stem cells (TDSCs). Nonsteroidal anti-inflammatory drugs have been demonstrated to alleviate age-associated inflammation (inflamm-aging)-induced cellular senescence of skeletal stem/progenitor cells. However, whether they can alleviate degenerative RCT through reducing inflamm-aging-related TDSC senescence is still unknown. PURPOSE: To assess whether celecoxib can prevent the inflamm-aging-related cellular senescence of TDSCs. STUDY DESIGN: Controlled laboratory study. METHODS: TDSCs were isolated from degenerative RCT tendons (S-TDSCs) and healthy hamstring tendons (Y-TDSCs), and the cellular senescence of TDSCs was evaluated. Thereafter, the senescent TDSC-conditioned medium (SEN-CM) was collected to culture Y-TDSCs with or without celecoxib. The effects of celecoxib on TDSC senescence were examined by assaying the expression of aging-related markers. Furthermore, the level of the NF-κB pathway was determined by Western blot analysis to explore the underlying mechanism. Its effects on preventing dysfunction of inflamm-aging-induced senescent TDSCs were also determined using multilineage differentiation assay. RESULTS: S-TDSCs showed increased senescence-associated β-galactosidase activity and enhanced expression of γ-H2AX, p21CIP1A, p16INK4A, and senescence-associated secretory phenotype factors. SEN-CM accelerated the senescence progress of Y-TDSCs, resulting in an increase in senescence markers. To some extent, celecoxib treatment could prevent the detrimental effects of inflamm-aging on Y-TDSCs. The level of the NF-κB pathway was increased in the SEN-CM group but decreased with the use of celecoxib. Moreover, the reduced senescence of TDSCs resulted in preservation of the TDSC tenogenic potential. CONCLUSION: Celecoxib treatment can prevent inflamm-aging-induced TDSC senescence, which holds potential for alleviating the development of degenerative RCT. CLINICAL RELEVANCE: In addition to relieving the symptoms of patients with RCT, treatment with celecoxib, a common nonsteroidal anti-inflammatory drug, may defer the development of RCT and prevent rotator cuff tears by delaying TDSC senescence.

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Cai Z, Zhang Y, Liu S, et al. Celecoxib, Beyond Anti-inflammation, Alleviates Tendon-Derived Stem Cell Senescence in Degenerative Rotator Cuff Tendinopathy. Am J Sports Med. 2022. PMID: 35666137. doi:10.1177/03635465221098133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。